Completed
Led by Massachusetts General Hospital · Updated on 2014-04-10
N/A
Participants Needed
N/A
Research Sites
N/A
Total Duration
M
Massachusetts General Hospital
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
To determine the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with atrial fibrillation without rheumatic heart disease.
CONDITIONS
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
You may qualify if you...
Men and women, 18 years of age or older, with non-rheumatic atrial fibrillation.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Site Locations not provided
Location information for this trial is currently unavailable.
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
RANDOMIZED
Model
N/A
Primary Purpose
PREVENTION
Number of Arms
0
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Daniel E Singer, Robert A Hughes...
https://pubmed.ncbi.nlm.nih.gov/2233931T R Lancaster, D E Singer, M A Sheehan...
https://pubmed.ncbi.nlm.nih.gov/1929681D E Singer, R A Hughes, D R Gress...
https://pubmed.ncbi.nlm.nih.gov/1462916J P Kistler, D E Singer, M M Millenson...
https://pubmed.ncbi.nlm.nih.gov/8362431